mirtazapine has been researched along with Parkinson Disease in 7 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mirtazapine-treated neuron-conditioned medium (Mir-NCM) induced astrocyte proliferation and upregulated MT expression via 5-HT1A receptors on astrocytes." | 1.56 | Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection. ( Asanuma, M; Kagawa, D; Kikuoka, R; Kitamura, Y; Kubota, N; Maeda, M; Miyazaki, I; Moriyama, M; Murakami, S; Sato, A; Sendo, T, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuoka, R | 1 |
| Miyazaki, I | 1 |
| Kubota, N | 1 |
| Maeda, M | 1 |
| Kagawa, D | 1 |
| Moriyama, M | 1 |
| Sato, A | 1 |
| Murakami, S | 1 |
| Kitamura, Y | 1 |
| Sendo, T | 1 |
| Asanuma, M | 1 |
| Tagai, K | 2 |
| Nagata, T | 2 |
| Shinagawa, S | 2 |
| Tsuno, N | 1 |
| Ozone, M | 1 |
| Nakayama, K | 2 |
| Hagikura, M | 1 |
| Iwamoto, K | 1 |
| Aleksic, B | 1 |
| Ozaki, N | 1 |
| Gordon, PH | 1 |
| Pullman, SL | 1 |
| Louis, ED | 1 |
| Frucht, SJ | 1 |
| Fahn, S | 1 |
| Normann, C | 1 |
| Hesslinger, B | 1 |
| Frauenknecht, S | 1 |
| Berger, M | 1 |
| Walden, J | 1 |
| Pact, V | 1 |
| Giduz, T | 1 |
7 other studies available for mirtazapine and Parkinson Disease
| Article | Year |
|---|---|
Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection.
Topics: Animals; Antioxidants; Astrocytes; Cells, Cultured; Dopamine; Dopaminergic Neurons; Female; Male; Me | 2020 |
Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
Topics: Aged, 80 and over; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Female; Halluc | 2013 |
What is a rational antidepressant treatment for major depression in patients with Parkinson's disease?
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Humans; Mianserin; Middle Aged | 2012 |
A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease.
Topics: Antidepressive Agents, Tricyclic; Basal Ganglia Diseases; Depressive Disorder; Female; Hallucination | 2013 |
Mirtazapine in Parkinsonian tremor.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Mianserin; Middle Aged; Mir | 2002 |
Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Depressive Disorder; Drug Interaction | 1997 |
Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias.
Topics: Adrenergic alpha-Antagonists; Aged; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; | 1999 |